Abstract: A sodium-cooled nuclear reactor includes at least one electromagnetic pump assembly and a backflow reduction pipe. The backflow reduction pipe may include an inlet, an outlet, at least one tubular section having a first length and a first diameter, and at least one fluid diode section between the inlet and the outlet.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: Methods, apparatus, systems and articles of manufacture to determine provenance for data supply chains are disclosed. Example instructions cause a machine to at least, in response to data being generated, generate a local data object and object metadata corresponding to the data; hash the local data object; generate a hash of a label of the local data object; generate a hierarchical data structure for the data including the hash of the local data object and the hash of the label of the local data object; generate a data supply chain object including the hierarchical data structure; and transmit the data and the data supply chain object to a device that requested access to the data.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: Provided herein are methods for the treatment of disease with monoacylglycerol lipase (MAGL) inhibitors.

Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Abstract: Methods, apparatus, systems and articles of manufacture to determine provenance for data supply chains are disclosed. Example instructions cause a machine to at least, in response to data being generated, generate a local data object and object metadata corresponding to the data; hash the local data object; generate a hash of a label of the local data object; generate a hierarchical data structure for the data including the hash of the local data object and the hash of the label of the local data object; generate a data supply chain object including the hierarchical data structure; and transmit the data and the data supply chain object to a device that requested access to the data.

Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Abstract: The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.

Abstract: A prefabricated window sill 10 suitable for external use comprises a closed cast outer shell 12 having at least an upper surface 16, a lower surface 18, a front surface 20, a rear surface 22 and first and second end surfaces 24, 26. The shell is made from a composite of a plastic polyester resin mixed with either crushed marble or crushed glass, with a catalyst which causes the resin to set; the shell being filled with an expanded plastics foam.

Abstract: The present invention relates to certain antiviral compounds of formula I as defined herein that function as nucleoside reverse transcriptase inhibitors. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions comprising them and to their use for the treatment of retroviral infections, and in particular their use in the treatment of HIV-1 virus.

Abstract: The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: A prefabricated window sill (10) suitable for external use comprises a closed cast outer shell (12) having at least an upper surface (16), a lower surface (18), a front surface (20), a rear surface (22) and first and second end surfaces (24, 26). The shell is made from a composite of a plastic polyester resin mixed with either crushed marble or crushed glass, with a catalyst which causes the resin to set; the shell being filled with an expanded plastics foam.